Pfizer Inc. $PFE Shares Bought by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,023,011 shares of the biopharmaceutical company’s stock after purchasing an additional 91,444 shares during the period. Rakuten Investment Management Inc.’s holdings in Pfizer were worth $29,381,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Third View Private Wealth LLC lifted its position in shares of Pfizer by 5.8% during the third quarter. Third View Private Wealth LLC now owns 16,939 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 923 shares in the last quarter. Provenance Wealth Advisors LLC increased its holdings in shares of Pfizer by 132.4% in the third quarter. Provenance Wealth Advisors LLC now owns 39,699 shares of the biopharmaceutical company’s stock valued at $1,132,000 after purchasing an additional 22,615 shares in the last quarter. Associated Banc Corp acquired a new stake in shares of Pfizer in the third quarter valued at approximately $2,862,000. Cumberland Advisors Inc. increased its holdings in shares of Pfizer by 8.4% in the third quarter. Cumberland Advisors Inc. now owns 77,300 shares of the biopharmaceutical company’s stock valued at $2,205,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Integrity Alliance LLC. raised its position in Pfizer by 2.0% in the 3rd quarter. Integrity Alliance LLC. now owns 114,957 shares of the biopharmaceutical company’s stock worth $3,279,000 after purchasing an additional 2,277 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 2.3%

Shares of NYSE:PFE opened at $29.98 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market cap of $170.85 billion, a price-to-earnings ratio of 39.44, a P/E/G ratio of 2.08 and a beta of 0.31. The company has a 50 day moving average of $28.64 and a 200-day moving average of $26.84. Pfizer Inc. has a one year low of $23.62 and a one year high of $31.06.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the business posted $0.87 earnings per share. Pfizer’s revenue was down .4% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.7%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is currently 226.32%.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. JPMorgan Chase & Co. upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. BMO Capital Markets dropped their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, Scotiabank raised their price target on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Five analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.65.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat earnings and revenue expectations, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its full-year revenue guidance to $62 billion–$64 billion, citing strong performance and momentum in newer and acquired medicines. Pfizer lifts FY26 guidance
• Positive Sentiment: Growth is broadening beyond COVID products: launched and acquired medicines grew 32%, with Eliquis, Padcev, Vyndaqel, Nurtec and Lorbrena among the products highlighted. Pfizer also cited progress in its obesity and oncology programs. Pfizer’s product growth
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. Her experience may support continuity in financial planning and capital allocation, though the appointment alone does not change the company’s outlook. Pfizer appoints Cecile Guegan CFO
• Negative Sentiment: Quarterly revenue was essentially flat year over year as COVID-related demand continued to fall: Paxlovid sales dropped 63% and Comirnaty sales declined 29%. The ongoing transition away from pandemic products leaves investors focused on whether newer medicines can offset those declines. Pfizer Q3 product sales
• Negative Sentiment: Despite the earnings beat and raised guidance, the stock eased. Investor caution may reflect expectations already embedded in the shares and uncertainty about the longer-term payoff from Pfizer’s acquisitions, pipeline and efforts to address upcoming patent expirations. Pfizer’s growth test ahead

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.